Del 164 i serien Progress in Molecular Biology and Translational Science

Cancer Immunotherapy

Inbunden, Engelska, 2019

2 789 kr

Beställningsvara. Skickas inom 7-10 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

Cancer Immunotherapy, Volume 165 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related to different approaches to cancer immunotherapy, with this release focusing on TNFR2 in cancer immunology and immunotherapy, From the Hellstrom paradox towards cancer cure, CAR T-cell treatment of T-cell malignancy , Immunotherapy of pancreatic cancer, Cancer stem cell immunology/immunotherapy,

Cytokine release syndrome, Tumor cell-based mechanisms of resistance to immune attack, and Mushroom compounds in cancer immunotherapy.

Includes comprehensive coverage of molecular biology
Presents ample use of tables, diagrams, schemata and color figures to enhance the reader's ability to rapidly grasp the information provided
Contains contributions from renowned experts in the field

Produktinformation

Utgivningsdatum2019-08-04
Mått152 x 229 x undefined mm
Vikt700 g
FormatInbunden
SpråkEngelska
SerieProgress in Molecular Biology and Translational Science
Antal sidor354
FörlagElsevier Science
ISBN9780128165751

Tillhör följande kategorier

Onkologi inom Medicin

David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid β-protein (Alzheimer's disease) and α-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.

1. TNFR2 in cancer immunology and immunotherapyXin Chen2. From the Hellstrom paradox towards cancer cureIngegerd Hellstrom and Karl Erik Hellstrom3. CAR T-cell treatment of T-cell malignancy Martin Pule4. Immunotherapy of pancreatic cancerJorg Kleeff5. Cancer stem cell immunology/immunotherapy Federica Cavallo6. Cytokine release syndromeAlexander Shimabukuro-Vornhagen7. Tumor Cell-Based Mechanisms of Resistance to Immune AttackLouis M. Weiner8. Mushroom compounds in cancer immunotherapyPeter Amwoga Ayeka